» Articles » PMID: 12015247

Multisystem Dystrophy Syndrome Due to Novel Missense Mutations in the Amino-terminal Head and Alpha-helical Rod Domains of the Lamin A/C Gene

Overview
Journal Am J Med
Specialty General Medicine
Date 2002 May 17
PMID 12015247
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Mutations in different domains of the LMNA (lamin A/C) gene encoding nuclear envelope proteins lamin A and lamin C cause familial partial lipodystrophy (Dunnigan variety), dilated cardiomyopathy, and autosomal dominant forms of Emery-Dreifuss and limb-girdle muscular dystrophies. The objective of this study was to evaluate LMNA variants in two families with familial partial lipodystrophy (Dunnigan variety) who also had cardiac conduction system defects and other manifestations related to cardiomyopathy. We performed mutational analysis of the lamin A/C gene in affected and unaffected subjects by deoxyribonucleic acid sequencing of the exons. Two novel missense mutations were identified in exon 1 of the lamin A/C gene. One mutation, R28W (CGG-->TGG), affected the amino-terminal head domain, and the other, R62G (CGC-->GGC), affected the alpha-helical rod domain. Affected subjects from both families had an increased prevalence of cardiac manifestations, such as atrioventricular conduction defects, atrial fibrillation, and heart failure due to ventricular dilatation, as well as pacemaker implantation. The proband from one of the families also had proximal muscle weakness. Novel genetic defects in the LMNA gene in two families with the Dunnigan variety of familial partial lipodystrophy, cardiac conduction system defects, and other manifestations related to cardiomyopathy suggest the occurrence of a multisystem dystrophy syndrome due to LMNA mutations.

Citing Articles

Lipodystrophic Laminopathies: From Dunnigan Disease to Progeroid Syndromes.

Diaz-Lopez E, Sanchez-Iglesias S, Castro A, Cobelo-Gomez S, Prado-Morana T, Araujo-Vilar D Int J Mol Sci. 2024; 25(17).

PMID: 39273270 PMC: 11395136. DOI: 10.3390/ijms25179324.


Deciphering the Clinical Presentations in LMNA-related Lipodystrophy: Report of 115 Cases and a Systematic Review.

Besci O, Foss de Freitas M, Guidorizzi N, Celik Guler M, Gilio D, Maung J J Clin Endocrinol Metab. 2023; 109(3):e1204-e1224.

PMID: 37843397 PMC: 10876415. DOI: 10.1210/clinem/dgad606.


Clinical Spectrum of -Associated Type 2 Familial Partial Lipodystrophy: A Systematic Review.

Fernandez-Pombo A, Diaz-Lopez E, Castro A, Sanchez-Iglesias S, Cobelo-Gomez S, Prado-Morana T Cells. 2023; 12(5).

PMID: 36899861 PMC: 10000975. DOI: 10.3390/cells12050725.


Phenotypic Differences Among Familial Partial Lipodystrophy Due to or Variants.

Vasandani C, Li X, Sekizkardes H, Brown R, Garg A J Endocr Soc. 2022; 6(12):bvac155.

PMID: 36397776 PMC: 9664976. DOI: 10.1210/jendso/bvac155.


Volanesorsen, an antisense oligonucleotide to apolipoprotein C-III, increases lipoprotein lipase activity and lowers triglycerides in partial lipodystrophy.

Lightbourne M, Startzell M, Bruce K, Brite B, Muniyappa R, Skarulis M J Clin Lipidol. 2022; 16(6):850-862.

PMID: 36195542 PMC: 9771980. DOI: 10.1016/j.jacl.2022.06.011.